Highly potent synthetic retinoid that has high affinity for RAR-α
receptors and low affinity for cellular retinoic acid binding protein (CRABP). Inhibits rabbit tracheal epithelial cell differentiation by inhibiting transglutaminase and increasing cholesterol sulfate (EC50
values are 0.02 and 0.03 nM respectively). Induces differentiation of embryonic carcinoma F9 and melanoma S91 cells (EC50
values are 0.26 and 0.5 nM respectively) and inhibits the induction of ornithine decarboxylase activity in 3T6 fibroblasts (EC50
= 1 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein.
Jetten et al.
Cancer Res., 1987;47:3523
Functional studies of newly sythesized benzoic acid derivatives: identification of highly potent retinoid-like activity.
Sato et al.
Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors (RAR's).
Hashimoto et al.
The citations listed below are publications that use Tocris products. Selected citations for Ch 55 include:
Showing Results 1 - 1 of 1